Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorFerrer Internacional S.A.
About this trial
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient consent
Males and females aged 18 years old or older
Confirmed diagnosis of diffuse parenchymal lung disease based on imaging (any form of ILD or CPFE)
Disqualifiers
Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD
Use of concomitant PAH drugs contraindicated for PH-ILD (ambrisentan and riociguat)
Use of any concomitant investigational drug
Trial design
Treatments tested in this trial
Inhaled Treprostinil
Drug
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov